(VIANEWS) – FibroGen Shares Plunge 12.78% and Halt Five-Session Winning Streak
At the close of trading on Tuesday, shares of FibroGen (NASDAQ: FGEN) fell 12.78% to EUR0.57 – breaking their five-session winning streak despite overall market gains such as the NASDAQ’s 0.25 increase to EUR14,220.81. Regardless, its 52 week high of EUR25.69 remains more than 97.56% below what FibroGen currently trades for.
About FibroGen
FibroGen Pharmaceuticals Inc is a biopharmaceutical company focused on creating therapeutics to meet unmet medical needs. Their lead products, Pamrevlumab and Roxadustat, are in various stages of clinical development to treat idiopathic pulmonary fibrosis, pancreatic cancer, Duchenne muscular dystrophy anemia associated with chronic kidney disease as well as myelodysplastic syndromes. Partnership agreements exist between FibroGen and Astellas Pharma Inc and AstraZeneca AB as well. Established in 1993 in San Francisco
Yearly Analysis
According to data provided, FibroGen’s stock is currently trading at EUR0.57 – significantly below its 52-week high of EUR25.69 but higher than its 52-week low of EUR0.33. This indicates that its value has experienced significant drop over the past year while experiencing some recovery since hitting its low point.
FibroGen anticipates an estimated sales growth for this year of 16.2%, giving investors confidence. Looking forward, its expected annual sales growth should increase moderately to 3.4% indicating moderate increase in revenue growth for the company.
FibroGen currently boasts an EBITDA value of 0.19, which may indicate insufficient profits being generated to sustain operations over the long-term. Investors should exercise caution regarding this low figure.
Before investing in FibroGen stock, investors should carefully evaluate its current stock price, sales growth projections and EBITDA value. Furthermore, conducting more in-depth research on its financials, market position and growth prospects would be wise before making their final decisions.
Technical Analysis
FibroGen stock is currently experiencing a steep decrease in value, falling below both its 50-day and 200-day moving averages, suggesting it may be in an imminent bearish trend. Furthermore, trading volume for FibroGen has significantly decreased from what would normally be expected and represents low investor enthusiasm in their shares.
FibroGen has demonstrated positive intraday variation averages over the past week, month and quarter indicating some level of price volatility. FibroGen had its highest average weekly volatility last week at 11.21% which may present investors with opportunities to take advantage of short-term fluctuations and make purchases during short price fluctuations.
According to the stochastic oscillator, FibroGen’s stock is currently considered oversold (=20), suggesting it may be undervalued at its current price level and offering potential investors an excellent buying opportunity.
Overall, FibroGen’s current stock price and technical indicators point towards an opportunity for investors who are comfortable taking on short-term price volatility in hopes of long-term gains. Before making any definitive investments decisions however, further investigation and research should be conducted by potential buyers.
Quarter Analysis
FibroGen appears to be experiencing strong sales and revenue growth based on available data. Current quarter sales growth was 14.3% while 21.3% is estimated for future quarter growth. This indicates that their sales are increasing at an upward trajectory which could signal good things for investors.
FibroGen projects growth estimates of 37.1% and 48.1% for this and next quarters respectively – indicative of continuing strong expansion over time.
Revenue growth at FibroGen was at 155% year-on-year for its twelve trailing months ending December 2018, with current revenue reaching 154.98M. This indicates a significant upswing in revenues over this time frame, which may be seen as positive sign by investors.
Overall, FibroGen seems like it holds significant growth potential; its rising sales and revenue could signal that its investment could pay dividends for investors. Before making your own decision about investing, however, be sure to conduct proper research and consider all relevant factors before taking action.
Equity Analysis
FibroGen reported trailing twelve month earnings of EUR-3.06 over the past year, which indicates negative earnings and potential financial challenges for the company. As an investor, it’s crucial to evaluate FibroGen’s profitability and growth potential before making investment decisions; you might want to investigate their financial statements or management team to discover any positive trends or growth opportunities which could offset its negative EPS number. Comparing FibroGen with industry peers or historical performance may give additional insight into its profitability.
More news about FibroGen (FGEN).
